Consistently, we found increased proportions of polyfunctional CD4+ T cell responses in CKD patients receiving three doses of mRNA vaccine BNT162b2 compared to a CoronaVac primary schedule with a BNT162b2 booster. Here, CD4 is linked to chronic kidney disease.